New research exposes hidden vulnerability in novel Coronavirus

By Nikita Chaurasia  Date: 2020-08-12

New research exposes hidden vulnerability in novel Coronavirus

The research led by Monica Olvera de la Cruz, Lawyer Taylor Professor of Materials Science and Engineering, and Baofu Qiao, a research assistant professor at the Northwestern University, have reportedly discovered a new vulnerability in the SARS-CoV-2 spike protein, indicating a relatively simple treatment route.

For those unfamiliar, the binding site present in the spike protein on attaching to host cells allows the virus to enter and multiply inside the body. Researchers were able to discover polybasic cleavage site, a positively charged site situated 10 nanometers from the actual binding site.

This positively charged site reportedly enables a strong bond between the spike protein and negatively charged human-cell receptors. Upon this discovery, the researchers devised a way to prevent the virus from bonding to the host cell by designing a negatively charged molecule that could bind with the positively charged cleavage site, cite credible sources.

Olvera de la Cruz claimed that the blocking the cleavage site could be a preventive treatment to reduce the virus’ capability of infecting human cells. The research shows that mutations of the SARS-CoV-2 spike protein impacted the transmission of the virus, she emphasized.  

The research was backed by the U.S. Department of Energy, Northwestern University’s Center for Computation and Theory of Soft Materials, and the Sherman Fairchild Foundation, claim sources.

With this new-found data, the researchers are eyeing to collaborate with Northwestern pharmacologists and chemists to develop a drug that could bind to the spike protein.

In another major development, Russain Microbiology Research Center Gamaleya have already announced the world’s first coronavirus vaccine.

The quest for finding a vaccine to combat the novel coronavirus, which was declared a pandemic on March 11 by the WHO, may finally reach a conclusion with many possible cures emerging into the scene.  

Sources:

https://news.northwestern.edu/stories/2020/08/research-exposes-new-vulnerability-in-sars-cov-2/

https://www.dnaindia.com/world/report-russia-registers-world-s-first-coronavirus-vaccine-president-putin-s-daughter-vaccinated-2837128/amp

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Netflix confirms producing fictionalized version of Spotify’s ascension

Netflix confirms producing fictionalized version of Spotify’s ascension

By Nikita Chaurasia

Over-the-top content streaming & production giant Netflix Inc. is reportedly working on an untitled series that tells the story of one of the most successful music streaming companies, Spotify Ltd. The six-part series, already listed on Netflix,...

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

By Nikita Chaurasia

Byju’s, the largest education technology company, has emerged as India’s highest-valued startup after a USD 340 million funding round involving investors such as UBS Group, Blackstone, and Zoom founder Eric Yuan among others. Recently, B...

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

By Nikita Chaurasia

Hesai Photonics Technology Co. Ltd., a leading Shanghai-based LiDAR company, has reportedly secured USD 300 million in a Series D funding round which was led by GL Ventures LLC, Xiaomi Corporation, Hillhouse Capital Group, Meituan, and CPE. The roun...

Tesla terminates production of its Model S Plaid + variant indefinitely

Tesla terminates production of its Model S Plaid + variant indefinitely

By Nikita Chaurasia

CEO Elon Musk justified Model S Plaid as good enough against its successor. The Model S Plaid + was touted to be Tesla’s flagship vehicle, with a range of around 519 miles. After unveiling for the first time last year, American EV maker T...

ByHeart concludes largest U.S. clinical trial for infant food product

ByHeart concludes largest U.S. clinical trial for infant food product

By Nikita Chaurasia

ByHeart Inc., a New-York based infant, and baby nutrition company, has recently announced the completion of the largest clinical trial for new infant formula in the past 25 years. With this move, the company is earmarked to be the 4th FDA registered,...